INS and type 2 diabetes mellitus: In the trial that evaluated the efficacy and safety of imeglimin as a combination therapy with insulin in Japanese type 2 diabetic patients, the incidence of adverse events, serious adverse events, and hypoglycemia was similar in the imeglimin and placebo groups [50].